GC
BIVV

GMT Capital’s Bioverativ Inc. Common Stock BIVV Stock Holding History

GMT Capital’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-108,250
Closed -$5.89M – 123
2017
Q1 		$5.89M Buy
+108,250
New +$5.33M 0.12% 84

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

GMT Capital's BIVV Position: Q2 2017 in Review

GMT Capital sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 108,250 shares — an estimated $5.89M sold.

GMT Capital first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $5.89M in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • GMT Capital reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • GMT Capital sold 108,250 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $5.89M.
  • GMT Capital first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • GMT Capital's Bioverativ Inc. Common Stock position peaked at $5.89M in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on GMT Capital's 13F filing for Q2 2017, filed 14 Aug 2017.